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The Fanconi Anemia (FA) pathway consists of proteins involved in repairing DNA damage, including interstrand cross-links
(ICLs). The pathway contains an upstream multiprotein core complex that mediates the monoubiquitylation of the FANCD2
and FANCI heterodimer, and a downstream pathway that converges with a larger network of proteins with roles in homologous
recombination and other DNA repair pathways. Selective killing of cancer cells with an intact FA pathway but deﬁcient in certain
other DNA repair pathways is an emerging approach to tailored cancer therapy. Inhibiting the FA pathway becomes selectively
lethal when certain repair genes are defective, such as the checkpoint kinase ATM. Inhibiting the FA pathway in ATM deﬁcient
cells can be achieved with small molecule inhibitors, suggesting that new cancer therapeutics could be developed by identifying FA
pathway inhibitors to treat cancers that contain defects that are synthetic lethal with FA.
1.Introduction
Fanconi anemia is a rare genetic disease featuring charac-
teristic developmental abnormalities, a progressive pancy-
topenia, genomic instability, and predisposition to cancer
[1,2].TheFApathwaycontainsamultiproteincorecomplex,
including at least twelve proteins that are required for the
monoubiquitylation of the FANCD2/FANCI protein com-
plex and for other functions that are not well understood [3–
6]. The core complex includes the Fanconi proteins FANCA,
FANCB, FANCC, FANCE, FANCF, FANCG, FANCL, and
FANCM. At least ﬁve additional proteins are associated with
the FA core complex, including FAAP100, FAAP24, FAAP20,
and the histone fold dimer MHF1/MHF2 [1, 4, 7–10]. The
core complex proteins function together as an E3 ubiqui-
tin ligase assembly to monoubiquitylate the heterodimeric
FANCI/FANCD2 (ID) complex. The monoubiquitylation of
FANCD2 is a surrogate marker for the function of the FA
pathway [11]. USP1 and its binding partner UAF1 regulate
the deubiquitination of FANCD2 [12]. The breast cancer
susceptibility and Fanconi proteins FANCD1/BRCA2, the
partner of BRCA2 (PALB2/FANCN), a helicase associated
with BRCA1 (FANCJ/BACH1), and several newly identi-
ﬁed components including FAN1, FANCO/RAD51C, and
FANCP/SLX4 [13–17] participate in the pathway to respond
to and repair DNA damage (for review, see [5]).
Although FA is rare, understanding the functional role of
the FA proteins in context with other DNA damage response
pathways will provide broader opportunities for new cancer
therapeutics. Two general strategies could accomplish this,
as illustrated in Figure 1: inhibiting the FA pathway in
tumor cells to sensitize them to cross-linking agents, or by
exploiting synthetic lethal relationships. The latter approach
depends on inhibiting the FA pathway in tumor cells that are
defective for a secondary pathway required for survival in the
absence of the FA pathway.
2. Chemosensitizing and Resensitizing
Tumor Cells
A deﬁning characteristic of FA cells is hypersensitivity to
cross-linking agents, such as the chemotherapeutic agent
cisplatin [2, 5]. Cisplatin (and other platinum-based2 Anemia
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Figure 1: Inhibition of the FA pathway. Strategy for selectively
targeting tumor cells by inhibition of the FA pathway by (a) chemo-
sensitization to cross-linking agents or by (b) exploiting speciﬁc
synthetic lethal interactions.
compounds) has been used as a chemotherapeutic drug
for over 30 years (for review see [18]). The toxicity of
platinum-based chemotherapy (nephrotoxicity, neurotoxic-
ity, and ototoxicity) and development of cisplatin resistance
are limitations of the therapy [18–20]. Once inside the cell,
cisplatin enters the nucleus and forms covalent DNA inter-
strand cross-links via platinum-DNA adducts. These cross-
links block ongoing DNA replication, and in the absence of
repair, activate apoptotic pathways [18, 19]. A functional FA
pathway is required for processing damage after exposure
to cisplatin and other crosslinking agents, and is at least
partially responsible for resistance to cisplatin. Cell-free and
cell-basedassayshaveidentiﬁedinhibitorsoftheFApathway,
and some of these inhibitors can resensitize platinum-
resistant tumors and cell lines [19, 21, 22]. Further eﬀorts to
identify small molecule compounds that speciﬁcally inhibit
the FA pathway could lead to improved resensitization from
treatment-induced resistance.
3.ExploitingSynthetic Lethal Interactions
In addition to sensitization, inhibiting the FA pathway may
be an eﬀective strategy to exploit synthetic lethal interactions
aimed at improving targeted killing of tumor cells. Current
approaches in cancer treatment are generally not selective,
aﬀecting both cancer cells and normal cells. However,
inactivation of DNA repair pathways, an event that occurs
frequently during tumor development [23], can make cancer
cellsoverdependentonareducedsetofDNArepairpathways
for survival. There is new evidence that targeting the remain-
ing functional pathways by using a synthetic lethal approach
can be useful for single-agent and combination therapies in
such tumors. Two genes have a synthetic lethal relationship
if mutants for either gene are viable but simultaneous
mutations are lethal [20]. A successful example of this
approach is speciﬁc targeting of BRCA-deﬁcient tumors with
PARP (poly (ADP-ribose) polymerase) inhibitors [24].
4. Defects in Homologous Recombination and
SensitivitytoPARP Inhibitors
Defects in HR repair can result in an overreliance on the
protein PARP1, which is responsible for repair of DNA
single strand breaks by the base excision repair pathway.
Unrepaired single-strand breaks are converted to double-
strand breaks during replication and must be repaired by HR
[25–27]. Thus, treating cells that are defective in HR with
PARP inhibitors results in a targeted killing of the defective
cells, while cells with intact HR are capable of repair.
Defects in breast cancer susceptibility proteins BRCA1 and
BRCA2 (FANCD1) result in HR defects [28]. Clinical trials
investigating the eﬀectiveness of PARP inhibitors against
recurrent ovarian cancer have been promising, but rigorous
stratiﬁcation of tumors for HR status or “BRCA-ness”
(defects in HR) is needed to identify the patients who
are likely to beneﬁt [29–31]. Future clinical trials with
PARP1 inhibitors in breast cancer may require combination
therapies, evaluation of resistance, and identiﬁcation of non-
BRCA biomarkers [32].
PARP1 Inhibition has also been shown to be selec-
tively toxic to ATM-defective tumor cell lines in vitro and
to increase radiosensitivity of other ATM-proﬁcient cell
lines, including nonsmall-cell lung cancer, medulloblastoma,
ependymoma, and high-grade gliomas [33–35]. In addition,
cell lines lacking functional Mre11 are sensitive to PARP1
inhibitors,strengtheningthecaseforcombineduseofPARP1
inhibitors with inhibitors of the FA pathway [36, 37].
PTEN (phosphatase and tensin homolog) is a tumor-
suppressor gene and one of the most commonly mutated
genes in human tumor cells [38, 39] (see Figure 2). PTEN
deﬁciency results in decreased expression of RAD51, which
is required for homologous recombination [38, 40]. PTEN
deﬁcient tumors are thus candidates for targeted therapy by
PARP1 inhibition [36, 38]. Although approximately 470,000
(48%) of 977,628 newly diagnosed cancers each year in
the US may have PTEN defects, only a subset of these
cancers will have PTEN mutations that result in homologous
recombination defects and sensitivity to PARP inhibitors
[28, 39, 41–51]. Current studies are aimed at determining
the relationship between PTEN loss, RAD51 expression, and
PARP1 inhibitor sensitivity [36]. Eﬀorts to asses HR status to
establish which PTEN mutations lead to an HR defect, and
determining under what circumstances RAD51 expression
could be used as a biomarker, will be useful to stratify and
predict PARP1 inhibitor sensitivity.
Synthetic lethal interactions with the FA pathway have
been explored. An siRNA-based screen of cells deﬁcient in
the Fanconi core complex protein, FANCG, showed that
ATM, PARP1, NBS1, and PLK1 were among the genes with
a synthetic lethal interaction [52] (see Table 1). The FA-ATM
synthetic lethal relationship is particularly interesting since
ATM deﬁciency has been reported in a subset of patients
with hematological malignancies, including mantle cell
lymphoma, chronic lymphocytic leukemia, and acute lym-
phoblastic leukemia [53, 54], making these potential targets
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Figure 2: PTEN defects in cancers. Types of cancer diagnosed annually in the US (orange oval), with the estimates for PTEN deﬁciencies
shown in each type (blue oval). An unknown percentage of tumors with PTEN deﬁciencies will have a defect in homologous recombination
(HR) repair, predicting sensitivity to treatment with PARP1 inhibitors (green oval).
Table 1: Function and expression of genes synthetically lethal with FA.
Gene synthetically lethal
with FA genes Function Expression in tumor cells
TREX2 [52] DNA exonuclease; SAGA complex pathway Expressed in most tumor cell lines [60]
PARP1 [52]B E R
Overexpressed in tumors, including
medulloblastoma, ependymoma, HGG, melanoma,
and breast cancers [35, 61–63]
PLK1 [52] Cell-cycle progression Over-expressed in many human tumors [64]
RAD6/HR6B [52] Switching of DNA polymerases Upregulated in metastatic mammary tumors [65]
CDK7 [52] Transcription Moderately over-expressed in tumor cell lines [66]
TP53BP1 [52] DSB sensing; ATM activation Underexpressed in most cases of triple negative
breast cancer [67]
ATM [52] DSB response kinase Under-expressed in some tumors, see Figure 3
NEIL1 [52] BER Expression reduced in 46% of gastric cancers [68]
RAD54B [52] HR Known to be mutated in cancer cell lines [69, 70]
NBS1 [52] DSB sensing; ATM activation Over-expressed in HNSCC tumors [71]
ADH5 [6] Formaldehyde processing Reduced expression in melanoma cells [72]4 Anemia
Table 2: ATM-deﬁciency in cancer.
Malignancy ATM-deﬁcient cell
lines/number tested
T-cell prolymphocytic leukemia [73] 17/32
Mantle cell lymphoma [53] 12/28
Rhabdomyosarcoma [74]7 / 1 7
Chronic lymphoblastic leukemia [54, 73] 16/50, 38/111
BRCA1-negative breast cancer [75] 12/36
BRCA2 negative breast cancer [75] 12/40
Acute lymphoblastic leukemia [54]4 / 1 5
Non-BRCA1/BRCA2 negative breast
cancers [75] 118/1106
Other lymphomas [53] 10/97
5.Inhibitingthe FAPathway
Inhibition of the FA pathway could occur at any point in the
multistep FA protein network, but a key predictive readout
for FA function and resistance to ICLs is the monoubiqui-
tylation of FANCD2 [11, 55]. Several inhibitors of FANCD2
monoubiquitylation have been identiﬁed including protea-
some inhibitors bortezomib and MG132, curcumin, and
the curcumin analogs EF24 and 4H-TTD [19, 22, 56, 57].
Curcumin, a natural product derived from turmeric, was
identiﬁedasaweakinhibitorofFANCD2monubiquitylation
in a cell-based screen [19]. We developed a cell-free assay in
Xenopus egg extracts to screen small molecules for stronger
and more speciﬁc inhibitors of FANCD2 monubiquityla-
tion. Unlike cell-based screening assays for small molecules
capable of inhibiting the FA pathway, the cell-free method
uncouples FANCD2 monoubiquitylation from DNA replica-
tion, thus focusing more speciﬁcally on the key biochemical
steps in a soluble context enriched for nuclear proteins and
capable of full genomic replication [22]. Screening in egg
extracts identiﬁed 4H-TTD, a compound with structural
similarity to curcumin as an inhibitor, and this inhibitory
eﬀect was veriﬁed in human cells [22, 57]. A series of cur-
cumin analogs were also tested, including EF24, a potent
monoketone analog of curcumin [58, 59]. The prediction
that an FA inhibitor would selectively kill ATM-deﬁcient
cells was tested in cell-based assays for synthetic lethality
in ATM-proﬁcient and ATM-deﬁcient cells. ATM-deﬁcient
cells treated with EF24 demonstrated an increased sensitivity
compared to ATM wt cells (see Figure 3)[ 22, 57]. The
increased lethality in ATM-deﬁcient cells provides evidence
for future synthetic lethal approaches with FA pathway
inhibitors in the treatment of ATM-deﬁcient tumors, and
other tumors with deﬁciencies in genes that are synthetically
lethal with FA (see Table 1)[ 6, 52].
6. Conclusion andFutureDirections
Understanding how the Fanconi anemia pathway functions
in concert with other DNA damage response networks is
essential for understanding genomic stability and for
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Figure 3: EF24 is selectively toxic to ATM-deﬁcient cells [57].
309ATM-deﬁcient and 334ATM wild type cells were treated with
the FA pathway inhibitor EF24. Cell viability was measured after 3
days by MTS assay. Each point represents the mean of 3 repeats.
Error bars represent standard deviation.
exploiting synthetic lethality for new cancer treatments.
New chemotherapeutic agents could be developed by iden-
tifying potent and speciﬁc inhibitors of the FA pathway,
for example, by screening for compounds that inhibit key
FA pathway steps (e.g., monoubiquitylation and deubiqui-
tylation of FANCD2/FANCI). While a long-term defect in
the function of the FA pathway would result in genomic
instability, short-term inhibition could provide a treatment
strategy for tumors with deﬁciencies in certain other DNA
repair pathways. Stringent identiﬁcation of additional genes
with synthetic lethal relationships with the FA pathway, and
identiﬁcation of malignancies with deﬁciencies or mutations
in genes that are synthetic lethal with FA will be required for
these tailored therapeutic approaches.
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